Tadalafil dosage is not one fixed number. Current U.S. tablet labeling uses different frameworks depending on whether tadalafil is being used for erectile dysfunction as needed, erectile dysfunction once daily, benign prostatic hyperplasia, or combined ED and BPH. Those frameworks use the same active drug but differ in strength, frequency and how treatment is scheduled.
For ED used as needed, the standard labeling framework starts at 10 mg before anticipated sexual activity, with 5 mg and 20 mg serving as lower and higher options based on efficacy and tolerability. For once-daily ED, labeling starts at 2.5 mg and allows an increase to 5 mg. BPH and combined ED/BPH use a standard 5 mg once-daily framework, with specific modifications appearing in certain renal-impairment and drug-interaction contexts.
This page explains those label structures rather than recommending a personal tadalafil dose. Detailed once-daily use belongs on the daily tadalafil page, detailed PRN treatment belongs on the as-needed tadalafil page, and the tablet strengths themselves are mapped separately on the tadalafil strengths page.
The central dosage distinction is regimen. Erectile dysfunction can be treated within either an as-needed or once-daily labeling framework, whereas BPH and combined ED/BPH are structured around once-daily treatment.
This makes a phrase such as tadalafil 5 mg ambiguous without additional context. Five milligrams can appear in daily ED, BPH, combined ED/BPH and as-needed ED labeling, while 10 mg and 20 mg are principally associated with as-needed ED treatment.
The following table summarizes the standard U.S. tablet-label framework before special-population or interaction-related modifications are considered.
| Indication | Regimen | Standard starting or recommended framework | Possible labeled adjustment | Frequency |
|---|---|---|---|---|
| ED | As needed | 10 mg | Decrease to 5 mg or increase to 20 mg based on efficacy and tolerability | Prior to anticipated sexual activity; generally not more than once per day |
| ED | Once daily | 2.5 mg | May increase to 5 mg based on efficacy and tolerability | Once daily at approximately the same time |
| BPH | Once daily | 5 mg | Special renal-impairment framework may begin at 2.5 mg | Once daily at approximately the same time |
| ED with BPH | Once daily | 5 mg | Special renal-impairment framework may begin at 2.5 mg | Once daily at approximately the same time |
The terms dose, dosage, strength and regimen are often used interchangeably in search queries, but they describe different parts of treatment. Strength is the amount of tadalafil in a tablet, while dose describes how much is administered at a particular time and regimen describes how that administration is scheduled.
Dosage is the broader framework that combines these elements with indication and frequency. A 5 mg tablet therefore cannot be interpreted correctly without knowing whether it is being used once daily for ED, once daily for BPH, for combined ED/BPH, or within the as-needed ED framework.
This distinction is especially important for tadalafil because the drug supports more than one labeled treatment pattern. The strengths guide focuses on the tablet presentations themselves; this page focuses on how those strengths fit into dosage frameworks.
| Term | Meaning | Tadalafil example |
|---|---|---|
| Strength | Amount of active ingredient in a dosage unit | 2.5 mg, 5 mg, 10 mg or 20 mg tablet |
| Dose | Amount administered at one time | Defined within the relevant label framework |
| Frequency | How often administration occurs | Once daily or as needed |
| Regimen | Pattern in which doses are used | Daily ED vs as-needed ED |
| Dosage framework | Dose plus frequency, indication and modification rules | Different for ED, BPH and ED/BPH |
For tadalafil used as needed for erectile dysfunction, current U.S. labeling describes 10 mg as the recommended starting dose for most patients, taken before anticipated sexual activity. The label allows that dose to be decreased to 5 mg or increased to 20 mg according to individual efficacy and tolerability.
The standard maximum dosing frequency in most patients is once per day. Labeling also notes that tadalafil used as needed has demonstrated improvement in erectile function compared with placebo for up to 36 hours after administration, but that response window should not be interpreted as a requirement to dose every 36 hours or as a continuous erection.
Timing, the response window and practical PRN use are intentionally not expanded into a full regimen guide here. Those questions belong on the tadalafil as-needed page, while this master page establishes where 5 mg, 10 mg and 20 mg sit within the dosage structure.
| As-needed ED element | Current U.S. label framework |
|---|---|
| Usual starting dose | 10 mg |
| Lower labeled option | 5 mg |
| Higher labeled option | 20 mg |
| Adjustment basis | Efficacy and tolerability |
| Standard maximum frequency | Not more than once per day in most patients |
| Scheduling | Prior to anticipated sexual activity |
The once-daily ED framework starts lower because it is designed around repeated administration rather than isolated as-needed dosing events. Current U.S. labeling describes 2.5 mg once daily as the recommended starting dose, taken at approximately the same time each day without regard to the timing of sexual activity.
The daily ED dose may be increased to 5 mg based on efficacy and tolerability. That 2.5-to-5 mg structure should not be compared directly with the 10-to-20 mg as-needed range as though the lower daily numbers represent weaker versions of the same regimen.
Repeated daily administration changes the exposure pattern and eventually produces steady-state concentrations. The clinical daily-use framework is covered more fully on the daily tadalafil guide, while the PK implications belong to the dedicated research pages.
| Daily ED element | Current U.S. label framework |
|---|---|
| Starting dose | 2.5 mg once daily |
| Labeled increase | May increase to 5 mg based on efficacy and tolerability |
| Timing | Approximately the same time every day |
| Relationship to sexual activity | Daily administration is not tied to the timing of sexual activity |
For the signs and symptoms of benign prostatic hyperplasia, the standard U.S. tadalafil tablet framework is 5 mg once daily, taken at approximately the same time every day. BPH therefore does not use the standard 10 mg or 20 mg as-needed ED framework.
Current labeling also contains a specific renal-impairment modification: for BPH with creatinine clearance of 30–50 mL/min, the recommended starting dose is 2.5 mg once daily, with an increase to 5 mg considered based on individual response. When creatinine clearance is below 30 mL/min or the patient is on hemodialysis, once-daily tadalafil for BPH is not recommended.
Those renal details are included here because they materially change the dosage framework, but the deeper exposure and kidney-function discussion belongs on the tadalafil and renal impairment page. The disease-specific role of tadalafil remains on the tadalafil for BPH page.
| BPH context | Label framework |
|---|---|
| Standard once-daily framework | 5 mg once daily |
| Creatinine clearance 30–50 mL/min | 2.5 mg once daily starting dose; increase to 5 mg may be considered based on response |
| Creatinine clearance below 30 mL/min or hemodialysis | Once-daily tadalafil for BPH is not recommended |
When erectile dysfunction and BPH coexist, current U.S. labeling uses a combined once-daily framework rather than combining a daily BPH dose with a separate as-needed ED dose. The standard labeled dose is 5 mg once daily, taken at approximately the same time every day.
As with BPH alone, renal impairment can modify that framework. In current labeling, creatinine clearance of 30–50 mL/min is associated with a 2.5 mg once-daily starting dose and possible increase to 5 mg based on response, while once-daily use is not recommended below 30 mL/min or in hemodialysis.
This combined indication has its own logic and should not be inferred from the ED-only or BPH-only frameworks. The disease-level context is covered separately on the tadalafil for ED and BPH page.
| ED + BPH context | Label framework |
|---|---|
| Standard | 5 mg once daily |
| CrCl 30–50 mL/min | 2.5 mg once daily starting dose; possible increase to 5 mg based on response |
| CrCl below 30 mL/min or hemodialysis | Once-daily use is not recommended |
The most visible difference between tadalafil regimens is numerical: daily ED treatment uses 2.5 mg or 5 mg, while as-needed ED treatment commonly uses 5 mg, 10 mg or 20 mg. Those numbers can be misleading if regimen is ignored.
Once-daily tadalafil produces repeated exposure and reaches steady state after continued administration, whereas an as-needed dose is interpreted as an individual dosing event. This is why 5 mg daily cannot be treated as mathematically equivalent to half of a 10 mg as-needed strategy or one quarter of a 20 mg strategy.
A direct practical comparison of spontaneity, timing, exposure and regimen tradeoffs belongs on the daily vs as-needed tadalafil page. The role of this dosage hub is to show how the labeling frameworks are constructed.
| Feature | Once-daily ED | As-needed ED |
|---|---|---|
| Starting framework | 2.5 mg once daily | 10 mg as needed |
| Other standard strengths | 5 mg | 5 mg and 20 mg |
| Schedule | Every day | Prior to anticipated sexual activity |
| Timing relative to sexual activity | Not tied to a specific sexual event | Dose is taken before anticipated sexual activity |
| Exposure pattern | Repeated dosing and steady-state exposure | Individual as-needed dosing events |
Tadalafil labeling does not present dosage changes as a simple progression toward the largest available tablet. In the as-needed ED framework, movement between 5 mg, 10 mg and 20 mg is framed around efficacy and tolerability. The once-daily ED framework similarly allows movement from 2.5 mg to 5 mg.
That wording matters because efficacy and tolerability are patient-specific clinical assessments rather than conclusions that can be made from the tablet strength alone. A user cannot infer that 20 mg is inherently preferable to 10 mg or that 5 mg daily is automatically preferable to 2.5 mg.
Special populations and interacting medicines can also impose different limits from the standard framework. Those label modifiers are separate from ordinary efficacy/tolerability adjustments and are summarized below.
| Type of dosage change | What drives it |
|---|---|
| Standard ED adjustment | Efficacy and tolerability within the labeled regimen |
| Renal-impairment modification | Kidney function and regimen context |
| Hepatic-impairment restriction | Severity of hepatic impairment and regimen type |
| Drug-interaction modification | Effect of interacting medicines on tadalafil exposure or blood pressure |
Renal impairment is one of the clearest examples of why tadalafil dosage cannot be summarized by one universal number. Current U.S. labeling changes both the amount and permitted frequency in some as-needed settings and restricts once-daily use in severe renal impairment.
For as-needed ED with creatinine clearance of 30–50 mL/min, current CIALIS labeling recommends a 5 mg starting dose not more than once per day and limits the maximum to 10 mg not more than once every 48 hours. With creatinine clearance below 30 mL/min or hemodialysis, the maximum is 5 mg not more than once every 72 hours.
Once-daily ED is not recommended when creatinine clearance is below 30 mL/min or in hemodialysis. BPH and ED/BPH have the separate 2.5 mg starting framework at creatinine clearance 30–50 mL/min described above. These are label-defined special-population rules, not a basis for self-calculating a renal dose.
| Regimen | Renal context | Current label framework |
|---|---|---|
| ED as needed | CrCl 30–50 mL/min | Start 5 mg; maximum 10 mg not more than once every 48 hours |
| ED as needed | CrCl below 30 mL/min or hemodialysis | Maximum 5 mg not more than once every 72 hours |
| ED once daily | CrCl below 30 mL/min or hemodialysis | Not recommended |
| BPH or ED/BPH once daily | CrCl 30–50 mL/min | Start 2.5 mg once daily; increase to 5 mg may be considered based on response |
| BPH or ED/BPH once daily | CrCl below 30 mL/min or hemodialysis | Not recommended |
Hepatic impairment is handled differently from renal impairment in the U.S. label. For as-needed tadalafil in mild or moderate hepatic impairment, the dose should not exceed 10 mg once per day. Use in severe hepatic impairment is not recommended.
Once-daily tadalafil has not been extensively evaluated in mild or moderate hepatic impairment, so current labeling advises caution if it is prescribed in that setting. Once-daily use is not recommended in severe hepatic impairment.
These statements are deliberately broader than a personalized liver-disease dosage recommendation. The metabolism and severity-specific rationale belongs on the tadalafil and hepatic impairment page.
| Regimen | Hepatic context | Current label position |
|---|---|---|
| As needed | Mild or moderate hepatic impairment | Should not exceed 10 mg once per day |
| As needed | Severe hepatic impairment | Use is not recommended |
| Once daily | Mild or moderate hepatic impairment | Not extensively evaluated; caution advised |
| Once daily | Severe hepatic impairment | Use is not recommended |
Tadalafil is metabolized primarily through CYP3A, so potent CYP3A inhibitors can increase tadalafil exposure and alter the label-defined dosage ceiling. This is an interaction-driven modifier rather than an ordinary choice between standard strengths.
Current labeling states that for tadalafil used as needed with potent CYP3A inhibitors such as ketoconazole or ritonavir, the maximum recommended dose is 10 mg and should not be exceeded more than once every 72 hours. For once-daily tadalafil in the presence of potent CYP3A inhibitors, the maximum recommended dose is 2.5 mg.
The enzyme and exposure mechanisms behind these restrictions belong on the tadalafil and CYP3A4 page. Their inclusion here is limited to showing how interacting drugs can override the usual dosage framework.
| Tadalafil regimen | Potent CYP3A inhibitor context |
|---|---|
| As needed | Maximum 10 mg, not more than once every 72 hours |
| Once daily | Maximum 2.5 mg |
Alpha-blockers illustrate another reason the indication has to be known before interpreting tadalafil dosage. For ED, current labeling states that patients receiving an alpha-blocker should be stable on that therapy before tadalafil is initiated and that tadalafil should begin at the lowest recommended dose.
For BPH, the label takes a different position: tadalafil is not recommended in combination with alpha-blockers for the treatment of BPH. That distinction means a general statement such as 'use a lower tadalafil dose with an alpha-blocker' would be incomplete and potentially misleading.
This page does not expand into the cardiovascular interaction mechanism because that belongs in the safety silo. The dosage-level takeaway is that concomitant medication rules can depend on the indication as well as the tadalafil regimen.
| Context | Current label approach |
|---|---|
| ED with an alpha-blocker | Patient should be stable on alpha-blocker therapy; tadalafil initiated at the lowest recommended dose |
| BPH with an alpha-blocker | Combination is not recommended for treatment of BPH |
Not every interaction leads to a smaller dose or longer interval. Some combinations are contraindicated, meaning the issue is not solved by choosing 2.5 mg or 5 mg instead of a higher tablet strength.
Current U.S. tadalafil labeling contraindicates use with organic nitrates because tadalafil can potentiate their hypotensive effect. It also contraindicates tadalafil with guanylate cyclase stimulators such as riociguat because of the risk of clinically important blood-pressure lowering.
This distinction is important on a dosage page because it prevents the strength framework from being misread as a universal method of risk reduction. Dose modification and contraindication are separate label concepts.
| Situation | Label concept |
|---|---|
| Organic nitrates | Contraindicated; not managed by simply choosing a lower tadalafil dose |
| Guanylate cyclase stimulators such as riociguat | Contraindicated |
| Potent CYP3A inhibitors | Dose/frequency limits rather than a universal contraindication |
| Renal impairment | Regimen-specific dose or frequency modification |
Current U.S. tadalafil tablet labeling states that tadalafil may be taken without regard to food. This means the standard dosage frameworks do not require a separate fasting dose or a different tablet strength simply because a meal is involved.
That does not make food a dosage-adjustment variable in the way renal impairment, hepatic impairment or potent CYP3A inhibition can be. Those factors can change label limits, whereas food does not change the standard tablet dose framework.
The underlying pharmacokinetic evidence and meal-effect comparison belong on the tadalafil food-effects page.
| Factor | Effect on standard tablet dosage framework |
|---|---|
| Food | Tadalafil tablets may be taken without regard to food |
| Renal impairment | Can change dose and/or frequency limits |
| Hepatic impairment | Can impose dose limits or make use not recommended |
| Potent CYP3A inhibitors | Can lower maximum dose or extend minimum interval |
Current U.S. labeling includes a specific BPH context in which tadalafil is used with finasteride when BPH therapy is initiated. In that framework, tadalafil is labeled at 5 mg once daily, taken at approximately the same time each day.
The labeling limits this tadalafil-plus-finasteride initiation context to up to 26 weeks. That duration statement belongs to the combination framework and should not be interpreted as a general 26-week limit on all tadalafil treatment.
This is a useful example of why dosage information should be read together with indication and concomitant therapy. A number such as 5 mg can recur across several contexts while the reason, duration and surrounding treatment structure differ.
| BPH combination context | Current label framework |
|---|---|
| Tadalafil used with finasteride to initiate BPH treatment | Tadalafil 5 mg once daily |
| Labeled combination period | Up to 26 weeks |
Cialis is the branded tadalafil product associated with the same active ingredient used in generic tadalafil tablets. Current U.S. CIALIS and generic tadalafil labeling describe the same core ED/BPH dosage frameworks: 10 mg as needed as the usual ED starting point, 2.5 mg once daily as the daily ED starting point, and 5 mg once daily for standard BPH and ED/BPH treatment.
The exact dosage forms currently listed for a specific product can differ even when the dosing instructions refer to the same clinical framework. For example, the current DailyMed CIALIS label lists 5 mg, 10 mg and 20 mg in its Dosage Forms and Strengths section while still describing a 2.5 mg once-daily ED starting framework.
That is why 'Cialis dosage' and 'tadalafil dosage' often point to the same clinical framework but should still be checked against the exact product label. Brand identity and finished-product detail are covered separately on the Cialis product page.
| Dosage context | Generic tadalafil framework | CIALIS framework |
|---|---|---|
| ED as needed | 10 mg starting framework; 5 mg or 20 mg based on efficacy/tolerability | 10 mg starting framework; 5 mg or 20 mg based on efficacy/tolerability |
| ED once daily | 2.5 mg starting framework; may increase to 5 mg | 2.5 mg starting framework; may increase to 5 mg |
| BPH | 5 mg once daily standard framework | 5 mg once daily standard framework |
| ED + BPH | 5 mg once daily standard framework | 5 mg once daily standard framework |
Tadalafil is also used in pulmonary arterial hypertension, but that indication belongs to a separate product and dosing context and should not be folded into an ED/BPH dosage table. The fact that the active ingredient is tadalafil does not make the ED/BPH and PAH labeling frameworks interchangeable.
For that reason, this page intentionally does not provide a PAH dose or attempt to compare PAH milligram amounts with 2.5 mg, 5 mg, 10 mg or 20 mg ED/BPH treatment. Readers looking for that indication should use the tadalafil for pulmonary arterial hypertension page or the Adcirca product guide.
Keeping those contexts separate prevents a broad tadalafil dosage query from collapsing distinct indications, formulations and product labels into one misleading dosing ladder.
| Product context | Handled on this page? |
|---|---|
| ED as needed | Yes |
| ED once daily | Yes |
| BPH | Yes |
| ED + BPH | Yes |
| Pulmonary arterial hypertension | No — separate indication and product-label context |
One common misconception is that 20 mg represents the normal tadalafil dose because it is the largest familiar ED/BPH tablet strength. In fact, the standard as-needed ED framework begins at 10 mg for most patients, while daily ED begins at 2.5 mg and standard BPH treatment uses 5 mg once daily.
Another misconception is that 5 mg always means daily tadalafil. Five milligrams also appears as the lower option within as-needed ED labeling, so the number alone does not identify frequency.
A third mistake is to treat special-population limits as alternative self-selected regimens. Renal impairment, hepatic impairment and potent CYP3A interactions are clinical contexts that modify the label framework; they are not instructions for users to calculate a different dose on their own.
| Misunderstanding | More accurate interpretation |
|---|---|
| 20 mg is the standard tadalafil dose | Standard dosage depends on indication and regimen; as-needed ED usually starts at 10 mg |
| 5 mg always means once daily | 5 mg appears in both daily and as-needed frameworks |
| Daily 5 mg is equivalent to half of a 10 mg as-needed dose | Daily and as-needed dosing create different exposure patterns |
| A lower tablet fixes every interaction | Some interactions require specific limits and some combinations are contraindicated |
| All tadalafil indications use the same dosage framework | ED/BPH and PAH product contexts must be kept separate |
Tadalafil dosage is best understood as several separate label frameworks. As-needed ED usually starts at 10 mg with 5 mg and 20 mg as adjustment options; once-daily ED starts at 2.5 mg with possible increase to 5 mg; and standard BPH or ED/BPH treatment uses 5 mg once daily.
Those standard frameworks can be modified by renal function, hepatic function and interacting medicines. In some circumstances the label lowers the allowable amount, extends the interval between doses, or states that once-daily use is not recommended. Contraindications such as nitrates are different again and are not solved by choosing a smaller tablet.
The important question is therefore not simply 'what is the tadalafil dose?' but 'for which indication, regimen and product context?' This page provides that label map while leaving individual prescribing decisions to clinical assessment.
U.S. labeling has two ED frameworks. For tadalafil used as needed, the usual starting dose in most patients is 10 mg before anticipated sexual activity, with possible adjustment to 5 mg or 20 mg based on efficacy and tolerability. For once-daily ED, the labeled starting dose is 2.5 mg once daily and may be increased to 5 mg.
Five milligrams is used in several contexts. It is the standard once-daily framework for BPH and combined ED/BPH, can be used once daily for ED, and also appears as the lower option in the as-needed ED framework. The number 5 mg therefore does not establish frequency by itself.
Both are part of the standard as-needed ED framework. Ten milligrams is the usual labeled starting dose for most patients, while 20 mg is the higher adjustment option based on efficacy and tolerability. A 20 mg tablet contains twice as much tadalafil as a 10 mg tablet but is not automatically the better option.
For the standard as-needed ED framework, current U.S. labeling states that the maximum recommended dosing frequency is once per day in most patients. Kidney function, interacting medicines and other clinical contexts can impose longer intervals.
Current U.S. labeling describes 2.5 mg once daily as the starting dose for daily ED treatment, taken at approximately the same time each day without regard to the timing of sexual activity. The dose may be increased to 5 mg based on efficacy and tolerability.
The standard U.S. labeling framework for BPH is 5 mg once daily at approximately the same time each day. In patients with creatinine clearance of 30–50 mL/min, current labeling specifies a 2.5 mg once-daily starting dose with possible increase to 5 mg based on response.
The standard combined ED/BPH framework is 5 mg once daily. Current labeling includes a 2.5 mg once-daily starting framework for patients with creatinine clearance of 30–50 mL/min, with possible increase to 5 mg based on individual response.
Twenty milligrams belongs to the standard as-needed ED strength framework, not the standard once-daily ED or BPH frameworks. Once-daily ED labeling uses 2.5 mg and 5 mg, while standard BPH and ED/BPH treatment uses 5 mg once daily.
Yes. Current U.S. tadalafil tablet labeling states that it may be taken without regard to food, so the standard tablet dosage framework does not require a different strength or fasting schedule because of meals.
It can. Current labeling modifies tadalafil dose and/or frequency according to renal function and regimen. For example, as-needed ED has lower dose and longer-interval limits in renal impairment, while once-daily use is not recommended in some severe renal contexts. The exact framework requires clinical interpretation rather than self-adjustment.
Hepatic impairment can change the label framework. For as-needed use in mild or moderate hepatic impairment, current labeling limits tadalafil to no more than 10 mg once per day; severe hepatic impairment is not recommended. Once-daily use requires caution in mild or moderate hepatic impairment and is not recommended in severe impairment.
Yes. Potent CYP3A inhibitors can raise tadalafil exposure, and current labeling limits as-needed tadalafil to a maximum of 10 mg no more than once every 72 hours in that context; once-daily tadalafil is limited to 2.5 mg. Other interactions can have different rules.
No. Organic nitrates are contraindicated with tadalafil because of the risk of excessive blood-pressure lowering. This contraindication is not removed by choosing a smaller tadalafil strength.
For the main U.S. ED, BPH and combined ED/BPH frameworks, current CIALIS and generic tadalafil labeling describe the same core dosing structures. Exact currently listed tablet presentations can differ by specific product, so product labeling still matters.
No. Pulmonary arterial hypertension belongs to a separate tadalafil product and indication context and should not be interpreted from the ED/BPH dosage framework. PAH dosing belongs on the dedicated pulmonary-hypertension and Adcirca pages.
There is no universally best tadalafil dose. The labeled framework depends on indication, daily versus as-needed use, efficacy, tolerability, kidney or liver function, interacting medicines and other clinical factors. This page explains the U.S. labeling structure rather than selecting an individual dose.